A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C

Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0150021. doi: 10.1128/AAC.01500-21. Epub 2021 Nov 1.

Abstract

Resistance to anti-HIV drugs has been a problem from the beginning of antiviral drug treatments. The recent expansion of combination antiretroviral therapy worldwide has led to an increase in resistance to antiretrovirals; understanding the mechanisms of resistance is increasingly important. In this study, we analyzed reverse transcriptase (RT) variants based on sequences derived from an individual who had low-level rebound viremia while undergoing therapy with abacavir, azidothymidine (AZT) (zidovudine), and (-)-l-2',3'-dideoxy-3'-thiacytidine (3TC) (lamivudine). The RT had mutations at positions 64, 67, 70, 184, and 219 and a threonine insertion after amino acid 69 in RT. The virus remained partially susceptible to the nucleoside RT inhibitor (NRTI) regimen. We show how these mutations affect the ability of NRTIs to inhibit DNA synthesis by RT. The presence of the inserted threonine reduced the susceptibility of the RT mutant to inhibition by tenofovir.

Keywords: HIV-1; base excision; drug resistance; nucleoside analogs; reverse transcriptase.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Amino Acids
  • Anti-HIV Agents* / chemistry
  • Anti-HIV Agents* / pharmacology
  • HIV Infections* / drug therapy
  • HIV Reverse Transcriptase / metabolism
  • HIV-1* / genetics
  • HIV-1* / metabolism
  • Humans
  • Lamivudine / pharmacology
  • Mutation / genetics
  • Reverse Transcriptase Inhibitors / chemistry
  • Zidovudine / pharmacology

Substances

  • Amino Acids
  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • HIV Reverse Transcriptase